GENEVA, June 24 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today the launch of the innovative individually adjustable electronic injection device RebiSmart(TM) for the self-administration of Rebif(R) (interferon beta-1a), the company's disease-modifying drug used to treat relapsing forms of multiple sclerosis (MS). RebiSmart(TM) is the first device of its kind in this indication and was specifically designed for ease of handling and use. The unique features of RebiSmart(TM) also introduce the potential for improved treatment adherence, helping patients receive the full benefit from their treatment.

RebiSmart(TM) is used with Rebif(R) multidose cartridges, each of which contains one week's worth of medicine. Interactive, on-screen instructions and signals guide patients through the injection process, individually adjustable comfort settings give patients more flexibility with injection duration and depth, helping minimize discomfort and pain.

"Making injection more comfortable for the patient is important to ensure optimal treatment outcomes in multiple sclerosis," said Dr. Virginia Devonshire, Assistant Professor of Neurology at the University of British Columbia in Vancouver, Canada. "The first electronic injection device in MS is an innovative approach and could contribute to increasing patient adherence to therapy."

Continue reading from the 4th Paragraph